Tag: PROMISE II
Results from PROMISE II pivotal trial published, reinforcing “transformational value” of...
Results from the PROMISE II pivotal trial investigating transcatheter arterialisation of the deep veins using the LimFlow system in so-called no-option chronic limb-threatening ischemia...
LimFlow raises US$40 millions in Series D financing
LimFlow recently announced it has closed a US$40 million (€36 million) oversubscribed Series D financing round.
A press release reports that new investors Longitude...
PROMISE II U.S. pivotal trial of device designed for ‘no-option’ CLTI...
Enrolment has been completed in the PROMISE II pivotal trial of the LimFlow deep vein arterialisation system designed to prevent amputations in so-called "no-option"...
LimFlow receives Japan PMDA approval for clinical study of minimally-invasive technology
LimFlow announced today that the Japanese Pharmaceuticals and Medical Devices Agency (PMDA) has approved its Clinical Trial Notification (CTN) for the Japanese cohort of...
